Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc Ord
(OP:
AZNCF
)
169.55
UNCHANGED
Streaming Delayed Price
Updated: 11:07 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc Ord
< Previous
1
2
3
4
5
6
7
8
Next >
Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial
January 25, 2022
Valneva SE (NASDAQ: VALN) has started booster vaccinations in adult participants from its Phase 3 pivotal trial, Cov-Compare. This booster extension is...
Via
Benzinga
Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows
January 24, 2022
A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or ...
Via
Benzinga
Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder
January 24, 2022
The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for...
Via
Benzinga
Lower COVID-19 Vaccine Sales Estimated Amid Less Severe Omicron Variant: Bloomberg
January 21, 2022
According to an analytics firm, Airfinity Ltd, evidence that omicron causes less-severe disease than earlier COVID-19 variants is expected to lower the growth in vaccine...
Via
Benzinga
AstraZeneca Rolls Out "Unprecedented' Three Year Survival Data For Imfinzi/Treme Combo In Liver Cancer
January 19, 2022
A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresectable...
Via
Benzinga
AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US
January 13, 2022
AstraZeneca Plc (NASDAQ: AZN) said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-...
Via
Benzinga
AstraZeneca's COVID-19 Vaccine Booster Against Omicron, Delta - New Data Supports Use
January 13, 2022
AstraZeneca Plc (NASDAQ: AZN) has posted preliminary data from an ongoing safety and immunogenicity trial of its COVID-19 shot, Vaxzevria. When given as a third...
Via
Benzinga
Adagio's COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies
January 13, 2022
Adagio Therapeutics Inc (NASDAQ: ADGI) shares gain during the premarket session after recent findings showing that ADG20 has neutralization activity against the omicron...
Via
Benzinga
Scorpion Therapeutics, AstraZeneca Ink Precision Medicines Pact For Hard-To-Target Cancer Proteins
January 13, 2022
AstraZeneca Plc (NASDAQ: AZN) has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines...
Via
Benzinga
Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact
January 03, 2022
Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small...
Via
Benzinga
Oxford Lab Study Suggests AstraZeneca's COVID-19 Booster Works Against Omicron
December 23, 2021
A three-dose course of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine is effective against the omicron coronavirus variant, data from an Oxford University lab...
Via
Benzinga
AstraZeneca - Amgen's Tezspire Biologic Scores FDA Approval For Severe Asthma
December 20, 2021
The FDA has approved AstraZeneca plc (NASDAQ: AZN) / Amgen Inc's (NASDAQ: AMGN) Tezspire (tezepelumab-ekko) as add-on maintenance treatment of adult...
Via
Benzinga
Johnson & Johnson's, Sputnik, Sinopharm COVID-19 Vaccines Show Weakness Against Omicron Variant: Study
December 17, 2021
COVID-19 vaccines from China's state-owned Sinopharm and Johnson & Johnson (NYSE: JNJ) and Russia developed Sputnik were found to produce little or no...
Via
Benzinga
AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant
December 16, 2021
New preclinical data released by AstraZeneca Plc (NASDAQ: AZN) shows that its long-acting antibody Evusheld (tixagevimab co-packaged with cilgavimab) works against...
Via
Benzinga
Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back
December 15, 2021
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) expect data from late-stage trials of its COVID-19 booster dose in Q1 2022, instead of this year....
Via
Benzinga
Samsung Biologics, AstraZeneca Expand Collaboration To Include COVID-19, Cancer Therapy
December 14, 2021
Samsung Biologics Co Ltd said it would continue its partnership with AstraZeneca Plc (NASDAQ: AZN) on manufacturing biopharmaceuticals. According to Samsung, the production...
Via
Benzinga
AstraZeneca's Dapagliflozin No Longer Authorized For Type 1 Diabetes In UK
December 10, 2021
On 25 October 2021, the marketing authorization holder for dapagliflozin withdrew the indication for type 1 diabetes across Europe and the U.K. The SGLT2 inhibitor...
Via
Benzinga
Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity
December 09, 2021
Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an...
Via
Benzinga
AstraZeneca's COVID-19 Therapy Wins FDA Approval As First Antibody To Prevent Infection In Immunocompromised
December 09, 2021
The FDA authorized the use of AstraZeneca Plc's (NASDAQ: AZN)antibody cocktail to prevent COVID-19 infections in individuals with weak immune systems or a...
Via
Benzinga
Exposures
COVID-19
Product Safety
Mix & Match Pfizer, AstraZeneca COVID-19 Vaccine With Moderna Shows Improved Immune Response
December 07, 2021
A British study evaluating mixing COVID-19 vaccines showed a better immune response in people after the first dose of AstraZeneca Plc (NASDAQ: AZN) or ...
Via
Benzinga
Exposures
COVID-19
Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder
December 07, 2021
Ionis Pharmaceuticals Inc (NASDAQ: IONS) has entered into a strategic collaboration agreement with AstraZeneca Plc (NASDAQ: AZN) to develop and...
Via
Benzinga
Valneva's COVID-19 Shot Fails As Booster In Pfizer/BioNTech Vaccinated Population
December 03, 2021
Valneva SE (NASDAQ: VALN) has responded to data published from the U.K COV-Boost COVID-19 vaccine trial that investigated the reactogenicity and immunogenicity of...
Via
Benzinga
Exposures
COVID-19
AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report
December 03, 2021
AstraZeneca Plc (NASDAQ: AZN) blocked an $8 billion takeover of Swedish Orphan Biovitrum AB (OTC: BIOVF) by withholding its 8% stake in SOBI from a buyout offer by...
Via
Benzinga
Possible New Links Identified With AstraZeneca COVID-19 Shot, Blood Clots
December 02, 2021
Scientists have identified a possible reason the AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine may cause blood clots after the use of the shot was limited to...
Via
Benzinga
Exposures
COVID-19
AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting
November 30, 2021
The FDA has granted priority review for AstraZeneca Plc's (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) for breast cancer....
Via
Benzinga
Exposures
Product Safety
AstraZeneca's COVID-19 Vaccine Turns Profitable In Q3; Reaffirms FY21 Guidance
November 12, 2021
AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine made a small contribution to earnings in Q3. It expects the shot to move to "modest profitability" on new...
Via
Benzinga
Exposures
COVID-19
AstraZeneca Plans To Set Up Separate Division For Vaccines & Antibody Therapies - Report
November 10, 2021
AstraZeneca plc (NASDAQ: AZN) is reportedly creating a separate division for vaccines and antibody therapies, primarily to focus on its COVID-19 shot and...
Via
Benzinga
Exposures
COVID-19
AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program With Inovio
November 01, 2021
MedImmune Limited, a unit of AstraZeneca Plc (NASDAQ: AZN), has notified Inovio Pharmaceuticals Inc (NASDAQ: INO) to terminate the DNA cancer vaccine...
Via
Benzinga
AstraZeneca To Offload Some Drug Rights To Covis Pharma For $270M
November 01, 2021
AstraZeneca Plc (NASDAQ: AZN) will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for $270 million. Covis will also...
Via
Benzinga
AstraZeneca's Imfinzi/Chemo Combo Strikes First Immunotherapy Wins In Bile Duct Cancer Trial
October 26, 2021
AstraZeneca Plc (NASDAQ: AZN) revealed topline results from the Phase 3 TOPAZ-1 study. Related: AstraZeneca Touts Longest Survival Update In Lung Cancer...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.